Recent approvals of Benlysta and Lupkynis highlight a shift towards targeted therapies with improved profiles. Despite challenges like high costs and heterogeneous disease presentation, opportunities ...

On the heels of last week’s lupus nephritis nod from the FDA, Roche’s Gazyva is proving once again that it still has new ...

The current recommended urine protein to creatinine ratio is arbitrary, and a lower bar would capture more lupus nephritis ...

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

The FDA has approved Gazyva (obinutuzumab) for treating adult patients with active lupus nephritis who are already on ...

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate ...

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring ...

The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. The approval for the ...

Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...